BlackRock Amends Intellia Therapeutics Stake, Signals Confidence
Ticker: NTLA · Form: SC 13G/A · Filed: Jan 8, 2024 · CIK: 1652130
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds a big chunk of Intellia, signaling institutional confidence.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 8, 2024, indicating its ownership of Intellia Therapeutics, Inc. Common Stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, passive stake in the gene-editing company. This matters to investors because BlackRock is a major institutional investor, and their sustained position can signal confidence in Intellia's long-term prospects, potentially influencing other investors.
Why It Matters
BlackRock's continued substantial ownership in Intellia Therapeutics suggests a vote of confidence from a major institutional investor, which can positively influence market perception and investor sentiment for the stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate negative or highly volatile changes for the stock.
Analyst Insight
A smart investor would view this as a routine update from a major institutional holder, confirming BlackRock's continued passive interest in Intellia Therapeutics, but it doesn't signal an immediate buy or sell action. It reinforces that Intellia remains on the radar of large funds.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Intellia Therapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 8, 2024 (date) — the filing date of the SC 13G/A
- 45826J105 (other) — the CUSIP number for Intellia Therapeutics Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Intellia Therapeutics for the foreseeable future. (BlackRock, Inc.) — high confidence, target: December 31, 2024
- Intellia Therapeutics' stock price will experience minor, if any, direct impact from this routine filing. (Intellia Therapeutics, Inc.) — high confidence, target: January 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
What is the subject company whose securities are being reported?
The subject company is Intellia Therapeutics, Inc., identified by CIK 0001652130.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Intellia Therapeutics, Inc. is 45826J105.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 8, 2024 regarding Intellia Therapeutics, Inc. (NTLA).